1688 related articles for article (PubMed ID: 30153823)
21. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
[TBL] [Abstract][Full Text] [Related]
22. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Cell-Free DNA in Stage I-IV Non-Small Cell Lung Cancer.
Jiang J; Adams HP; Yao L; Yaung S; Lal P; Balasubramanyam A; Fuhlbrück F; Tikoo N; Lovejoy AF; Froehler S; Fang LT; Achenbach HJ; Floegel R; Krügel R; Palma JF
J Mol Diagn; 2020 Feb; 22(2):228-235. PubMed ID: 31837429
[TBL] [Abstract][Full Text] [Related]
23. Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay.
Remon J; Swalduz A; Planchard D; Ortiz-Cuaran S; Mezquita L; Lacroix L; Jovelet C; Rouleau E; Leonce C; De Kievit F; Morris C; Jones G; Mercier K; Howarth K; Green E; Pérol M; Saintigny P; Besse B
PLoS One; 2020; 15(6):e0234302. PubMed ID: 32525942
[TBL] [Abstract][Full Text] [Related]
24. Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications.
Hahn AW; Gill DM; Maughan B; Agarwal A; Arjyal L; Gupta S; Streeter J; Bailey E; Pal SK; Agarwal N
Oncotarget; 2017 May; 8(20):33614-33620. PubMed ID: 28431395
[TBL] [Abstract][Full Text] [Related]
25. Comparative analysis of genomic profiles between tissue-based and plasma-based next-generation sequencing in patients with non-small cell lung cancer.
Lin Z; Li Y; Tang S; Deng Q; Jiang J; Zhou C
Lung Cancer; 2023 Aug; 182():107282. PubMed ID: 37392713
[TBL] [Abstract][Full Text] [Related]
26. Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients.
Tran LS; Pham HT; Tran VU; Tran TT; Dang AH; Le DT; Nguyen SL; Nguyen NV; Nguyen TV; Vo BT; Dao HT; Nguyen NH; Tran TH; Nguyen CV; Pham PC; Dang-Mai AT; Dinh-Nguyen TK; Phan VH; Do TT; Truong Dinh K; Do HN; Phan MD; Giang H; Nguyen HN
PLoS One; 2019; 14(12):e0226193. PubMed ID: 31841547
[TBL] [Abstract][Full Text] [Related]
27. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
Zugazagoitia J; Ramos I; Trigo JM; Palka M; Gómez-Rueda A; Jantus-Lewintre E; Camps C; Isla D; Iranzo P; Ponce-Aix S; García-Campelo R; Provencio M; Franco F; Bernabé R; Juan-Vidal O; Felip E; de Castro J; Sanchez-Torres JM; Faul I; Lanman RB; Garrido P; Paz-Ares L
Ann Oncol; 2019 Feb; 30(2):290-296. PubMed ID: 30535340
[TBL] [Abstract][Full Text] [Related]
28. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
[TBL] [Abstract][Full Text] [Related]
29. Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
Sim WC; Loh CH; Toh GL; Lim CW; Chopra A; Chang AYC; Goh LL
Lung Cancer; 2018 Oct; 124():154-159. PubMed ID: 30268455
[TBL] [Abstract][Full Text] [Related]
30. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.
Wu Z; Yang Z; Li CS; Zhao W; Liang ZX; Dai Y; Zhu Q; Miao KL; Cui DH; Chen LA
Cancer Med; 2019 Mar; 8(3):910-919. PubMed ID: 30767431
[TBL] [Abstract][Full Text] [Related]
31. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
Roosan MR; Mambetsariev I; Pharaon R; Fricke J; Husain H; Reckamp KL; Koczywas M; Massarelli E; Bild AH; Salgia R
Chest; 2021 Sep; 160(3):1095-1107. PubMed ID: 33878340
[TBL] [Abstract][Full Text] [Related]
32. Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients.
Xu S; Lou F; Wu Y; Sun DQ; Zhang JB; Chen W; Ye H; Liu JH; Wei S; Zhao MY; Wu WJ; Su XX; Shi R; Jones L; Huang XF; Chen SY; Chen J
Cancer Lett; 2016 Jan; 370(2):324-31. PubMed ID: 26582655
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the somatic mutations between circulating tumor DNA and tissue DNA in Chinese patients with non-small cell lung cancer.
Zhang M; Feng Y; Qu C; Meng M; Li W; Ye M; Li S; Li S; Ma Y; Wu N; Jia S
Int J Biol Markers; 2022 Dec; 37(4):386-394. PubMed ID: 35791673
[TBL] [Abstract][Full Text] [Related]
34. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.
Iwama E; Sakai K; Azuma K; Harada T; Harada D; Nosaki K; Hotta K; Ohyanagi F; Kurata T; Fukuhara T; Akamatsu H; Goto K; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
Ann Oncol; 2017 Jan; 28(1):136-141. PubMed ID: 28177428
[TBL] [Abstract][Full Text] [Related]
35. Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients.
Dono M; De Luca G; Lastraioli S; Anselmi G; Dal Bello MG; Coco S; Vanni I; Grossi F; Vigani A; Genova C; Ferrarini M; Ravetti JL; Zupo S
Mol Med; 2019 Apr; 25(1):15. PubMed ID: 31029076
[TBL] [Abstract][Full Text] [Related]
36. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
37. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.
Schrock AB; Welsh A; Chung JH; Pavlick D; Bernicker EH; Creelan BC; Forcier B; Ross JS; Stephens PJ; Ali SM; Dagogo-Jack I; Shaw AT; Li T; Ou SI; Miller VA
J Thorac Oncol; 2019 Feb; 14(2):255-264. PubMed ID: 30368012
[TBL] [Abstract][Full Text] [Related]
38. CONCORDANCE: A real-world evidence study to evaluate the concordance of detecting epidermal growth factor receptor (EGFR) mutation by circulating tumor DNA* versus tissue biopsy in patients with metastatic non-small cell lung cancer.
Prabhash K; Biswas B; Khurana S; Batra U; Biswas G; Advani SH; Mohapatra PN; Rajappa S; Sharma A; Patil S; Dattatreya PS; Roy R; Almel S; Goyal G; Warrier N
Indian J Cancer; 2022 Mar; 59(Supplement):S11-S18. PubMed ID: 35343188
[TBL] [Abstract][Full Text] [Related]
39. Detection and Quantification of ctDNA for Longitudinal Monitoring of Treatment in Non-Small Cell Lung Cancer Patients Using a Universal Mutant Detection Assay by Denaturing Capillary Electrophoresis.
Benesova L; Ptackova R; Halkova T; Semyakina A; Svaton M; Fiala O; Pesek M; Minarik M
Pathol Oncol Res; 2022; 28():1610308. PubMed ID: 35837614
[No Abstract] [Full Text] [Related]
40. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
